

III. 研究成果の刊行に関する一覧表レイアウト

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
(分担) 考藤達哉	国の肝炎および肝がん対策	一般社団法人 日本肝臓学会	肝がん白書	日本印刷	東京	2022	44-47
(分担) 田中純子	わが国における肝癌の動向	一般社団法人 日本肝臓学会	肝がん白書	日本印刷	東京	2022	8-14

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Mino M, Kakazu E, Sano A, Katsuyama H, Hakoshima M, Yanai H, Aoki Y, Imamura M, Yamazoe T, Mori T, Yoshio S, Inoue J, Masamune A, <u>Kanto T.</u>	Effects on sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB-4 index in metabolic-associated fatty liver disease.	<i>Hepatol Res.</i>		1-11	2023
<u>Shimakami T,</u> <u>Setoyama H,</u> <u>Oza N,</u> <u>Itakura J,</u> <u>Kaneko S,</u> <u>Korenaga M,</u> <u>Toyama T,</u> <u>Tanaka J,</u> <u>Kanto T*.</u>	Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan.	<i>J Gastroenterol</i>	58	257-267	2023
Kuramoto J, Arai E, Fujimoto M, Tian Y, Yamada Y, Yotani T, Makiuchi S, Tsuda N, Ojima H, Fukai M, Seki Y, Kasama K, Funahashi N, Udagawa H, Nammo T, Yasuda K, Taketomi A, <u>Kanto T,</u> Kanai Y.	Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis.	<i>Clin Epigenetics.</i>	14	168	2022

Kawai H, Osawa Y, Tsunoda T, Matsuda M, Okawara M, Sakamoto Y, Shimagaki T, Tsutsui Y, Yoshida Y, Yoshikawa S, Doi H, Mori T, Yamazoe T, Yoshio S, Okamura T, Sugiyama M, Okuzaki D, Komatsu H, Inui A, Yanaga K, Ikegami T, <u>Kanto T.</u>	Peripheral-dominant liver fibrosis and tumor distribution in a mouse model of congestive hepatopathy.	<i>Hepatol Res</i>	53	370-376	2022
Terahara K, Li TC, Matsubayashi K, Sakata H, Kato T, Naganuma A, Ogawa K, Honda K, Itakura J, Akutsu N, Tobita H, Korenaga M, <u>Kanto T.</u> , Sugiyama R, Suzuki R, Hamaguchi I, Isogawa M, Takahashi Y.	Calibrating hepatitis E virus serological assays using asymptomatic specimens obtained in Japan.	<i>Microbiol Spectr.</i>	10	e0214622	2022
Tsutsui Y, Yoshio S, Tomiyama T, Shimagaki T, Itoh S, Harada N, Yoshida Y, Yoshikawa S, Kakazu E, <u>Kanto T.</u> , Yoshizumi T.	Preoperative serum brain-derived neurotrophic factor as a predictive biomarker for sepsis after living-donor liver transplantation.	<i>Hepatol Res.</i>	53	72-83	2023
Korenaga M, Murata K, Izumi N, Tamaki N, Yokosuka O, Takehara T, Sakamoto N, Suda G, Nishiguchi S, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Yamasaki K, Ide T, Toda N, Kanda T, Nirei K, Ueno Y, Haga H, Nishigaki Y, Nakane K, Omata M, Mochizuki H, Aoki Y, Imamura M, <u>Kanto T.</u> , Mizokami M.	No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.	<i>Glob Health Med.</i>	4	216-224	2022

Hussain MRA, Hiebert L, Sugiyama A, Ouoba S, Bunthen E, Ko K, Akita T, Kaneko S, <u>Kanto T</u> , Ward JW, <u>Tanaka J</u> .	Effect of COVID-19 on hepatitis B and C virus countermeasures: Hepatologist responses from nationwide survey in Japan.	<i>Hepatol Res</i>	52	899-907	2022
Kimura M, Nishikawa K, Osawa Y, Imamura J, Yamaji K, Harada K, Yatsuhashi H, Murata K, Miura K, Tanaka A, <u>Kanto T</u> , Kohara M, Kamisawa T, Kimura K.	Inhibition of CBP/ β -catenin signaling ameliorated fibrosis in cholestatic liver disease.	<i>Hepatol Commun</i>	6	1732-2747	2022
Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, <u>Kanto T</u> , Kubo S, Yoshiji H, Miyata H, Izumi N, Kudo M, Koike K.	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL)	<i>J Gastroenterol</i>	57	587-597	2022
<u>Tanaka J</u> , Kurisu A, Ohara M, Ouoba S, Ohisa M, Sugiyama A, Wang ML, Hiebert L, <u>Kanto T</u> , Akita T.	Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study.	<i>Lancet Reg Health West Pac</i>	22	100428	2022
Kimura K, <u>Kanto T</u> , Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T.	Safety, tolerability, and anti-fibrotic efficacy of the CBP/ β -catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.	<i>EBioMedicine</i> .	80	1-14	2022
Kaneko S, Kurosaki M, Kurisu A, Akita T, Tanaka J, <u>Kanto T</u> .	Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis.	<i>Hepatol Res</i> .	52	665-676	2022

Zhang H, Itoh Y, Suzuki T, Ihara KI, Tanaka T, Haga S, Enatsu H, Yumiya M, Kimura M, Takada A, Itoh D, Shibazaki Y, Nakao S, Yoshio S, Miyakawa K, Miyamoto Y, Sasaki H, Kajita T, Sugiyama M, Mizokami M, Tachibana T, Ryo A, Moriishi K, Miyoshi E, <u>Kanto T</u> , Okamoto T, Matsuura Y.	Establishment of monoclonal antibodies broadly neutralize infection of hepatitis B virus.	<i>Microbiol Immunol.</i>	66	179-192	2022
Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsushashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, <u>Kanto I</u> , Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.	Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis	<i>J Gastroenterol.</i>	57	120-132	2022
Kawai H, Osawa Y, Mtasuda M, Tsunoda T, Yanagida K, Hishikawa D, Okawara M, Sakamoto Y, Shimagaki T, Tsutsui Y, Yoshida Y, Yoshikawa S, Hashi K, Doi H, Mori	Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.	<i>Hepatology</i>	76	112-125	2022

Shinoda H, Watanabe Y, Fukai K, Kasuya K, Furuya Y, Nakazawa S, Honda T, Hayashi T, Nakagawa T, Tatemichi M, <u>Korenaga M.</u>	Significance of Fib4 index as an indicator of alcoholic hepatotoxicity in health examinations among Japanese male workers: a cross-sectional and retrospectively longitudinal study.	<i>Eur J Med Res.</i>	28	31	2023
Nakazawa S, Fukai K, Furuya Y, Hoshi K, Kojimahara N, Toyota A, <u>Korenaga M,</u> Tatemichi M	Occupational class and risk for hepatitis B and C viral infection.	<i>J Infect Public Health.</i>	15	1415-1426	2022
<u>Shimakami T,</u> Setoyama H, Oza N, Itakura J, Kaneko S, Korenaga M, Toyama T, Tanaka J, Kanto T.	Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan	<i>J Gastroenterol</i>	58(3)	257-267	2023
Sumiyadorj A, Murai K, <u>Shimakami T,</u> Kuroki K, Nishikawa T, Kakuya M, Yamada A, Wang Y, Ishida A, Shirasaki T, Kawase S, Li YY, Okada H, Nio K, Kawaguchi K, Yamashita T, Sakai Y, Duger D, Mizukoshi E, Honda M, Kaneko S.	A single hepatitis B virus genome with a reporter allows the entire viral life cycle to be monitored in primary human hepatocytes.	<i>Hepato Commun</i>	6(9)	2441-2454	2022
Li YY, Kuroki K, <u>Shimakami T,</u> Murai K, Kawaguchi K, Shirasaki T, Nio K, Sugimoto S, Nishikawa T, Okada H, Orita N, Takayama H, Wang Y, Thi Bich PD, Ishida A, Iwabuchi S, Hashimoto S, Shimaoka T, Tabata N, Watanabe-Takahashi M, Nishikawa K, Yanagawa H, Seiki M, Matsushima K, Yamashita T, Kaneko S, Honda M.	Hepatitis B virus utilizes a retrograde trafficking route via the trans-Golgi network to avoid lysosomal degradation.	<i>Cell Mol Gastroenterol Hepatol</i>	15(3)	533-558	2022

Shirasaki T, Yamagoe S, Shimakami T, Murai K, Imamura R, Ishii KA, Takayama H, Matsumoto Y, Tajima-Shirasaki N, Nagata N, Shimizu R, Yamanaka S, Abe A, Omura H, Kawaguchi K, Okada H, Yamashita T, Yoshikawa T, Takimoto K, Taharaguchi M, Takatsuka S, Miyazaki Y, Tamai T, Tanabe Y, Kurachi M, Yamamoto Y, Kaneko S, Matsumoto K, Takamura T, Honda M.	Leukocyte cell-derived chemotaxin 2 is an antiviral regulator acting through the proto-oncogene MET	Nat Commun	13(1)	3176	2022
武部貴則、西井正造	新しい医療を築く「スト リートメディカル」の発 想	医療福祉建築	218	14 - 15	2023
佐藤大樹, 出口亮, 小林洋平, 渡辺広道, 大迫真里子, 片岡公 一, 鈴木伸治, 秋 元康幸, 西井正造, 武部貴則.	建設作業所と公共の場 でのウェルビーイングに寄 与する空間の探索	アーバンインフ ラ・テクノロジー 推進会議	第34回技術 研究発表会		2022
佐藤大樹, 出口亮, 小林洋平, 渡辺広道, 大迫真里子, 片岡公 一, 鈴木伸治, 秋 元康幸, 西井正造, 武 部貴則.	ウェルビーイングの向上 に寄与する建築・まちづ くりに関する研究	大成建設技術セ ンター報	55	2	2022
西井正造、武部貴則	イネープリング・ファク ターとこれからの病院像	病院設備	64	14 - 17	2022

Keitoku T, <u>Tamaki N</u> , Kurosaki M, Inada K, Kirino S, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Ishido S, Yamada M, Nobusawa T, Matsumoto H, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Asahina Y, Okamoto R, Izumi N.	Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy	<i>J Viral Hepat</i>	30	297-302	2023
Huang DQ, <u>Tamaki N</u> , Lee HW, Park SY, Lee YR, Lee HW, Lim SG, Lim TS, Kurosaki M, Marusawa H, Mashiba T, Kondo M, Uchida Y, Kobashi H, Furuta K, Izumi N, Kim BK, Sinn DH	Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis	<i>Hepatology</i>	77	1746-1756	2023
Kaneko S, Kurosaki M, Mashiba T, Marusawa H, Kondo M, Kojima Y, Uchida Y, Fujii H, Akahane T, Yagisawa H, Kusakabe A, Kobashi H, Abe T, Yoshida H, Ogawa C, Furuta K, <u>Tamaki N</u> , Tsuji K, Matsushita T, Izumi N; Japanese Red Cross Liver Study Group.	Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B	<i>J Med Virol</i>	95	e28210.	2023

Kirino S, <u>Tamaki N</u> , Kurosaki M, Kaneko S, Inada K, Tanaka Y, Ishido S, Yamashita K, Nobusawa T, Matsumoto H, Hayakawa Y, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N.	Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	<i>Hepatol Res</i>	53	35-42	2023
Tada T, Kurosaki M, <u>Tamaki N</u> , Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Fujii H, Ishii T, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Nakamura S, Izumi N.	General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy	<i>JGH Open</i>	8	487-495	2022
Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, Tang ASP, Lim KE, Lim GEH, <u>Tamaki N</u> , Kim BK, Teng MLP, Fung J, Loomba R, Nguyen MH, Huang DQ	Risk of Hepatocellular Carcinoma with Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis	<i>JAMA Netw Open</i>	5	e2219407	2022
Tokunaga T, Tateyama M, Kondo Y, Miura S, Miyase S, Tanaka K, Narahara S, Inada H, Kurano S, Yoshimaru Y, Nagaoka K, Watanabe T, <u>Setoyama H</u> , Fukubayashi K, Tanaka M, Tanaka Y	Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.	<i>Cancers</i>	15	1568	2023

Narahara S, Watanabe T, Nagaoka K, Fujimoto N, Furuta Y, Tanaka K, Tokunaga T, Kawasaki T, Yoshimaru Y, <u>Setoyama H</u> , Oniki K, Saruwatari J, Tateyama M, Naoe H, Tanaka M, Tanaka Y, Sasaki Y	Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.	<i>Hepatology Communications</i>	6	1198-1212	2022
Matsuno K, Miyamoto H, Kitada H, Yoshimatsu S, Tamura F, Sakurai K, Fukubayashi K, Shono T, <u>Setoyama H</u> , Matsuyama T, Suko S, Narita R, Honda M, Tateyama M, Naoe H, Morinaga J, Tanaka Y, Gushima R	Comparison of endoscopic submucosal resection with ligation and endoscopic submucosal dissection for small rectal neuroendocrine tumors: A multicenter retrospective study.	<i>DEN Open</i>	3	E163	2022
Imajo K, Toyoda H, Yasuda S, Suzuki Y, Sugimoto K, Kuroda H, Akita T, <u>Tanaka J</u> , Yasui Y, Tamaki N, Kurosaki M, Izumi N, Nakajima A, Kumada T	Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort	Clinical gastroenterology and hepatology			In press
Ichikawa H, Yasuda E, Kumada T, Takeshima K, Ogawa S, Tsunekawa A, Goto T, Nakaya K, Akita T, <u>Tanaka J</u>	Intra-individual comparison of liver stiffness measurements by magnetic resonance elastography and two-dimensional shear-wave elastography in 888 patients	Ultrasonography	42(1)	65-77	2023
Toyoda H, Yasuda S, Shiota S, Kumada T, <u>Tanaka J</u>	Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response	European Journal of Gastroenterology and Hepatology	34(6)	693-697	2022
Sugiyama A, Kurisu A, Akita T, <u>Tanaka J</u>	Authors' response to "prevalence and incidence of fatty liver for people who took part in a health checkup in 2008-2019 in Japan"	Liver International	42(6)	1478	2022

Tada T, Kumada T, Matono T, Nakamura S, Sue M, Matuo Y, Masahiro T, Iijima H, <u>Tanaka J</u>	Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance	Journal of gastroenterology and hepatology open	6(7)	462-469	2022
Kumada T, Toyoda H, Yasuda S, Ogawa S, Gotoh T, Tada T, Ito T, Sumida Y, <u>Tanaka J</u>	Combined ultrasound and magnetic resonance elastography predict hepatocellular carcinoma after hepatitis C virus eradication	Hepatology Research	52(11)	957-967	2022
Sugiyama A, Kurisu A, E B, Ouoba S, Ko K, Rakhimov A, Akita T, Harakawa T, Sako T, Koshiyama M, Kumada T, <u>Tanaka J</u>	Distribution of FIB-4 index in the general population - Analysis of 75,666 residents who underwent health checkups-	BMC gastroenterology	22(1)	241	2022
Hussain Md RA, Hiebert L, Sugiyama A, Ouoba S, Bunthen E, Ko K, Akita T, Kaneko S, <u>Kanto T</u> , Ward JW, <u>Tanaka J</u>	Effect of COVID-19 on hepatitis B and C virus countermeasures: Hepatologist responses from nationwide survey in Japan	Hepatology Research	52(11)	899-907	2022
Kumada T, Toyoda H, Yasuda S, Ito T, Tsuji K, Fujioka S, Hiraoka A, Kariyama K, Nouso K, Ishikawa T, Tamai T, Tada T, <u>Tanaka J</u>	Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus	Journal of Viral Hepatitis	29(10)	919-929	2022
Blach S et al. (<u>Tanaka J</u> 259 人中 6 番目)	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study	The LANCET Gastroenterology and Hepatology	7(5)	396-415	2022
Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, <u>Tanaka J</u>	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection	European Radiology	32(7)	5016-5023	2022

Kaneko S, Kurosaki M, Kurisu A, Akita T, Tanaka J, Kanto T	Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis	Hepatology Research	52(8)	665-676	2022
El-Ekiaby M, Tanaka J, van Drimmelen H, Allain JP, Lelie N	Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?	Journal of Viral Hepatitis	29(5)	330-339	2022
Kumada T, Ogawa S, Goto T, Toyoda H, Yasuda S, Ito T, Yasuda E, Akita T, Tanaka J	Intra-individual comparisons of the ultrasound-guided attenuation parameter and the magnetic resonance imaging-based proton density fat fraction using bias and precision statistics	Ultrasound in Medicine and Biology	48(8)	1537-1546	2022
Kumada T, Toyoda H, Yasuda S, Ogawa S, Gotoh T, Ito T, Tada T, Tanaka J	Liver stiffness measurements by 2D shear-wave elastography: Effect of steatosis on fibrosis evaluation	American journal of roentgenology	219(4)	604-612	2022
Toyoda H, Yasuda S, Moriya A, Itobayashi E, Uojima H, Watanabe T, Atsukawa M, Arai T, Ishikawa T, Mikami S, Hiraoka A, Tsuji K, Oikawa T, Tsubota A, Nozaki A, Chuma M, Abe H, Shima T, Kumada T, Tanaka J	Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy	Journal of Infection and Chemotherapy	28(9)	1231-1234	2022
E B, Ou P, Ouoba S, Hussain Md RA, Ko K, Nagashima S, Sugiyama A, Akita T, Tanaka J	Prevalence and genotype distribution of viral hepatitis B in Cambodia between 1990 and 2020: A Systematic Review and Meta-analysis	Archives of Public Health	80(1)	119	2022

Nagaoki Y, Sugiyama A, Mino M, Kodama H, Abe K, Imada H, Ouoba S, E B, Ko K, Akita T, Sako T, Kumada T, Chayama K, <u>Tanaka J</u>	Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	Hepatology Research	52(11)	908-918	2022
Hayes NC, Imamura M, <u>Tanaka J</u> , Chayama K	Road to elimination of HCV: Clinical challenges in HCV management	Liver International	42(9)	1935-1944	2022
Toyoda H, Atsukawa M, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Itobayashi E, Watanabe T, Matsuura K, Shimada N, Abe H, Tsuji K, Itokawa N, Mikami S, Ishikawa T, Oikawa T, Yasuda S, Chuma M, <u>Tanaka J</u>	The Impact of cirrhosis and history of hepatocellular carcinoma on all-cause mortality after eradication of hepatitis C virus in patients with chronic hepatitis C	Gastro Hep Advances	1(4)	508	2022
<u>Tanaka J</u> , Kurisu A, Ohara M, Ouoba S, Ohisa M, Sugiyama A, Wang ML, Hiebert L, <u>Kanto T</u> , Akita T	Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study	The Lancet regional health. Western Pacific	22()	100428	2022
Kikuchi M, Sawabe M, Aoyagi H, Wakae K, Watashi K, Hattori S, Kawabe N, Yoshikawa K, <u>Tanaka J</u> , Muramatsu M, Wakita T, Aizaki H	Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers	Hepatology International	16(1)	68-80	2022
Kumada T, Toyoda H, Yasuda S, Ito T, <u>Tanaka J</u>	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population	Hepatology Research	52(1)	81-92	2022